The firm’s revenue from biosimilars grew 25% in the latest quarter. | Photo Credit: DHIRAJ SINGH Biocon expects a 50% drop in costs for developing complex…
Trending
- 6 Reasons Why the Orbi 370 is the Best Mesh WiFi for Streaming
- WOL3D shares dip despite 82% revenue jump in H1 results
- 467. The Mamdani Method Explained: Could It Shock Britain?
- IRS Ends IRS Direct File. Here’s Why & Free Alternatives.
- Colorado River States Miss Deadline as Crisis Deepens
- Cristiano Ronaldo sees red as Troy Parrott double fires Republic of Ireland to victory
- Galaxy Z TriFold leak reveals massive screen, impressive specs, and unusual design quirk
- US proposal to halve biosimilar development costs for Biocon, top exec says
